'Skinny labels' on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period
Summary by Ground News
The provision is known as skinny labeling, which refers to a move by a company that seeks regulatory approval to market a generic or biosimilar medicine. By doing so, the company seeks to avoid lawsuits in which the brand-name manufacturer could claim patent infringement. Medicare saved $1.5 billion from 2015 to 2020, or nearly 5% of the $30.2 billion spent by the health care program.Published 2 months ago
News Articles
More Filters
All
Left
Center
Right
Time & Location
Sources are mostly out of (0)
Bias Distribution
100% of the sources are Center
C 100%
See less detail
